Core Viewpoint - TC BioPharm (Holdings) PLC continues trading on the Nasdaq Global Select Market under the ticker symbol 'TCBP', indicating stability in its market presence and ongoing operations [1][2]. Company Overview - TC BioPharm is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for cancer treatment, with human efficacy data specifically in acute myeloid leukemia [3]. - The company is recognized as a leader in the development of gamma-delta T cell therapies and is the first to conduct phase II/pivotal clinical studies in oncology [4]. Clinical Trials - TC BioPharm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for treating acute myeloid leukemia using its proprietary allogeneic CryoTC technology, which allows for the provision of frozen products to clinics globally [4].
TCBP Trading Continues Unabated on Nasdaq Stock Exchange